loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Copanlisib Dihydrochloride

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Copanlisib Dihydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bayer, Novo separately opt to discontinue their Aliqopa, Levemir
    Bayer, Novo separately opt to discontinue their Aliqopa, Levemir

    10 Nov 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/its-end-line-bayers-p13k-aliqoba-and-novos-insulin-levemir-after-two-market-pulls

    Zoey Becker FIERCE PHARMA
    10 Nov 2023
    Share Share
    Bayer to pull follicular lymphoma drug Aliqopa from US market
    Bayer to pull follicular lymphoma drug Aliqopa from US market

    08 Nov 2023

    // Ayisha Sharma ENDPTS

    https://endpts.com/bayer-to-pull-follicular-lymphoma-drug-aliqopa-from-us-market-in-another-blow-to-the-pi3k-inhibitor-space/

    Ayisha Sharma ENDPTS
    08 Nov 2023
    Share Share
    Bayer Submits Regulatory Applications for Aliqopa and rituximab Combo
    Bayer Submits Regulatory Applications for Aliqopa and rituximab Combo

    21 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210621005100/en

    BUSINESSWIRE
    21 Jun 2021
    Share Share
    Investigational Combination of Aliqopa® and rituximab Significantly
    Investigational Combination of Aliqopa® and rituximab Significantly

    16 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210410005037/en/Investigational-Combination-of-Aliqopa%C2%AE-copanlisib-and-rituximab-Significantly-Increases-Progression-Free-Survival-in-Patients-with-Relapsed-Indolent-non-Hodgkins-Lymphoma

    BUSINESSWIRE
    16 Apr 2021
    Share Share
    Investigational Combination of Aliqopa® (copanlisib) and rituximab
    Investigational Combination of Aliqopa® (copanlisib) and rituximab

    09 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210410005037/en

    BUSINESSWIRE
    09 Apr 2021
    Share Share
    Pharming deal shows there's still life in struggling cancer drug class
    Pharming deal shows there's still life in struggling cancer drug class

    16 Aug 2019

    // J. Gardner BIOPHARMADIVE

    https://www.biopharmadive.com/news/pharming-deal-novartis-cancer-drug-pi3k-immune/561007/

    J. Gardner BIOPHARMADIVE
    16 Aug 2019
    Share Share